Clene Receives $7.2 Million Year-4 NIH Grant Subaward With NYU for ALS Program
Clene Inc. received a $7.2 million subaward from NYU under an NIH grant to support its Expanded Access Program for CNM-Au8, a treatment for ALS. The agreement, signed on Oct 15, 2026, covers the period from Sep 1, 2026, to Aug 31, 2027, according to the company's SEC filing.
How this was made
The 30-second read
Why it matters
The funding supports the Expanded Access Program, reducing financing risk and signaling continued regulatory interest.
Market read
A small but positive catalyst for a micro‑cap biotech; limited broader market impact.
What to watch
Potential future FDA interactions or additional funding rounds not disclosed.
Background
Clene (CLNN) filed an 8‑K reporting a year‑four NIH subaward amendment with NYU for up to $7.2 M to support its CNM‑Au8 ALS treatment.
Ticker impact
Clene disclosed a new $7.2 million NIH subaward for its ALS program, first public filing (8‑K).
modest upside as investors price in the new funding and reduced near‑term financing risk
Small grant size limits market move, but biotech investors typically react positively to any FDA‑related funding.
Market effects
Adds a data point to the ALS biotech niche, may slightly boost peer sentiment.
U.S. biotech sector sees a minor positive cue.
Limited; primarily relevant to investors in small‑cap biotech.
Counterpoint
The grant is modest and may not materially affect cash runway; price could remain flat.
Key entities
- companyClene Inc.
Biotech firm developing CNM‑Au8 for ALS.
- institutionNew York University
Partner institution receiving the NIH subaward.
